-
Barron’s: Insider Stock Transactions
Monday, December 7, 2009 - 3:13pm | 227For the week ended 30 November 2009, the following were insider purchases: 100,000 shares in DirecTV (NASDAQ: DTV), 91,500 shares in Werner Enterprises (WERN), 100,000 shares in Zions Bancorporation (NASDAQ: ZION), 30,500 shares in Rofin Sinar Technologies (NASDAQ: RSTI), 2,774,306 shares in Fusion...
-
Sequenom (SQNM) Still On Shaky Ground
Thursday, December 3, 2009 - 3:45pm | 150Sequenom, Inc.(NASDAQ: SQNM) is a diagnostics testing and genetics analysis company. Its products and services are aimed at translating the results of genomic science for use in research and medical applications. The firm is on the rebound from a clinical study scandal that led to the dismissal of...
-
New 52-Week High Stocks (SRLS, GSIT, SEED, IOC)
Tuesday, December 1, 2009 - 11:23am | 194SeraCare Life Sciences, Inc. (NASDAQ: SRLS) hits a new 52-week high at $4.20 in today’s morning trade. Currently, SRLS is trading at $4.12, up 6.94% on 19K shares. In the last six months, SRLS climbed up over 310%. GSI Technology, Inc. (NASDAQ: GSIT) soared 15.58% to $5.38 on 2.75 million shares....
-
Benzinga’s Top Pre- Market Losers (LTON, OVTI, LINC, NLST, HGSI, NUVA, AFFX)
Tuesday, December 1, 2009 - 10:04am | 327Linktone Ltd. (ADR) (NASDAQ: LTON) decreased $0.33 or 13.98% to $2.03 in the pre-market session. Yesterday, LTON reported that for 4Q2009, it expects gross revenues to be in between $14 to $15 million. The 52-week trading range for LTON is $0.70 - $3.21. So far in the current year, LTON climbed up...
-
Setback for Theravance - Analyst Blog
Monday, November 30, 2009 - 2:38pm | 368Theravance (THRX) received a major setback in the approval process of Vibativ (telavancin) for the treatment of nosocomial pneumonia (NP). Recently, the company received a complete response letter (CRL) regarding this from the US Food and Drug Administration (FDA). Although the original...
-
Benzinga’s Top Pre- Market Gainers (PDLI, NVAX, SIMG, ALTH, SEED, SQNM, VVUS)
Monday, November 30, 2009 - 9:37am | 262PDL BioPharma Inc. (NASDAQ: PDLI) climbed 5.50% to $7 in the pre-market session. The 52 week trading range for PDLI is $5.20 - $9.92. So far in 2009, PDLI gained around 7%. Novavax, Inc. (NASDAQ: NVAX) jumped 6.67% to $3.20 in the pre-market session. The 52 week trading range for NVAX is $0.52 - $...
-
NASDAQ Most Traded, November 27
Friday, November 27, 2009 - 2:32pm | 221Shares of Intel (NASDAQ: INTC) were down a tick, just over 1% to $19.12 on a fairly sleepy trading day. The drop follows Wednesday’s issue of the government’s durable goods report for October, which revealed a drop in the computers and related products segment. Microsoft (NASDAQ: MSFT) similarly...
-
Is Sequenom (SQNM) a Speculative Play?
Friday, November 27, 2009 - 1:48pm | 81Shares of Sequenom Inc. (NYSE: SQNM) continue on the upside today, up $.044 to $4.29, on heavy volume. The stock is up over 11% while the broader indices are on the downside due to the Dubai debt problems. With no news on SQNM, it could be a speculative play. Top institutional holders of SQNM...
-
Benzinga’s Top Gainers (HEB, SQNM, APWR, QLTI, SOMX)
Friday, November 27, 2009 - 12:16pm | 166Hemispherx BioPharma, Inc (AMEX: HEB) soared 22% to $1.46 in the falling market. So far this year, HEB has moved up 314%. The 52-week range for HEB is $0.26-$4.54. A-Power Energy Generation Systems, Ltd. (NASDAQ: APWR) surged 7.55% to $17.53 on high volume of 1.85 million shares. Today APWR...
-
Benzinga’s Top Pre- Market Losers (PDLI, DRAM, LIHR, ATPG, JDSU, SQNM, CHOP, ABIO)
Friday, November 27, 2009 - 9:25am | 247PDL BioPharma Inc. (NASDAQ: PDLI) decreased $1.52 or 18% to $6.85. The 52-week trading range for PDLI is $5.20 - $9.92. So far in 2009, PDLI gained over 35%. Dataram Corporation (NASDAQ: DRAM) tumbled 5.16% to $3.86 in the pre-market session. In the last trading session, DRAM closed at $4.07. The...
-
Benzinga’s Biggest Losers (CWTR, DRAM, CONN, BNHN, SQNM, ZQK)
Wednesday, November 25, 2009 - 1:00pm | 226Coldwater Creek Inc. (NASDAQ: CWTR)plunged 15.51% to $4.52 huge volume of 2.99 million shares after CWTR reported its third quarter net loss of $33.9 million against $1.3 million loss from the same quarter last year. CWTR’s net sales for the third quarter stood at $266.6 million from $228.4 million...
-
Benzinga’s Top Pre- Market Gainers (TIF, RFMD, AIXG, INCY, SOLF, QGEN, CYTX, SVA)
Wednesday, November 25, 2009 - 9:40am | 359Tiffany & Co. (NYSE: TIF) rose 6.26% to $44.45 in the pre-market session after TIF announced that for the fourth quarter, it expects sales to increase and also provided outlook for fiscal 2009. For financial year 2009, TIF expects EPS to be in between $1.88 - $1.98 while analysts are expecting...
-
Why is Sequenom Stock Seeing Such Action?
Tuesday, November 24, 2009 - 10:33pm | 102Shares of Sequenom, Inc. (Nasdaq: SQNM), a life sciences company, rose 39.43% today, up $1.25 to $4.42. In after-hours trading, the stock hit a high of $4.56, with over 870,000 shares traded. For a stock that trades an average daily volume of 2,199,000---it’s something worth watching. There was a...
-
Benzinga's Volume Movers (PEET, CBRL, GPRE, NUAN)
Tuesday, November 24, 2009 - 3:05pm | 292Some of the company’s stocks saw extraordinary trading today in the morning. Some of the companies worth having a look are: Green Plains Renewable Energy Inc (NASDAQ: GPRE) shares moved 9.70% to $12.89. The volume of GPRE shares traded was 338% more than normal. Over the past six months, GPRE’s...
-
Biogen's Rituxan Label Expansion Delayed - Analyst Blog
Friday, November 20, 2009 - 12:00pm | 493Biogen Idec (BIIB) and Genentech, Inc., a wholly-owned member of the Roche Group (RHHBY.PK), announced that they have received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for Rituxan. The companies were seeking approval for the use of Rituxan (rituximab) plus...